Alivus Life Sciences Ltd.

NSE: ALIVUS | BSE: 543322 | ISIN: INE03Q201024 | Industry: Pharmaceuticals
| Mid-range Performer
1049.0000 6.45 (0.62%)
NSE Apr 10, 2026 14:55 PM
Volume: 46,438
 

logo
Alivus Life Sciences Ltd.
29 Apr 2023
1049.00
0.62%
buy
by BOB Capital Markets Ltd.
Target: 600
BOB Capital Markets Ltd.
Q4 revenue of Rs 6.2bn (+21% YoY) beat our estimate by 14% driven by recovery in CDMO and growth in API
 
Number of FII/FPI investors increased from 92 to 98 in Dec 2025 qtr.
More from Alivus Life Sciences Ltd.
Recommended
Market trades higher, Sun Pharma to buy US-based debt-ridden Organon for $12 billion
Trendlyne Marketwatch | 10 Apr 2026, 02:42PM
After the drop, are stock market valuations finally reasonable?
The Baseline | 09 Apr 2026, 03:18PM
Glenmark Life Sciences: The hived off API business of Glenmark Pharma goes public
| 27 Jul 2021